Abstract: A therapeutic agent or a preventive agent for alopecia areata has an ROR? antagonistic activity, and, there is a therapeutic agent or a preventive agent for alopecia areata, including a cyclic amine derivative typified by the following compound or a pharmacologically acceptable salt thereof as an active ingredient.

Abstract: A cyclic amine derivative represented by general Formula (I): wherein R1 represents an alkyl group having 1 to 3 carbon atoms; A represents a group represented by general Formula (II-1), (II-2), or (II-3): R2 represents a hydrogen atom or a halogen atom; R3 represents an aryl group or a cycloalkyl group having 4 to 6 carbon atoms, wherein any 1 or 2 hydrogen atoms of the aryl or cycloalkyl group represented by R3 may be each independently substituted with an alkyl group having 1 to 3 carbon atoms or an alkyloxy group having 1 to 3 carbon atoms, and wherein any 1 to 3 hydrogen atoms of the alkyl or alkyloxy group having 1 to 3 carbon atoms which can be a substituent of the aryl or cycloalkyl group may be each independently substituted with a halogen atom; n represents 1 or 2; or a pharmacologically acceptable salt thereof.

Abstract: A therapeutic agent or a preventive agent for alopecia areata has an ROR? antagonistic activity, and, there is a therapeutic agent or a preventive agent for alopecia areata, including a cyclic amine derivative typified by the following compound or a pharmacologically acceptable salt thereof as an active ingredient.

Abstract: A compound has inhibitory activity on Discoidin Domain Receptor 1. The compound includes a urea derivative represented by the formula below or a pharmaceutically acceptable salt thereof.

Abstract: A compound has retinoid-related orphan receptor ? antagonist activity and shows a therapeutic effect or a preventive effect on autoimmune diseases such as multiple sclerosis or psoriasis or allergic diseases, including allergic dermatitis or the like, such as contact dermatitis or atopic dermatitis. The cyclic amine derivative is represented by the formula or a pharmacologically acceptable salt thereof.

Abstract: A compound has inhibitory activity on Discoidin Domain Receptor 1. A urea derivative is represented by the formula (I) or a pharmaceutically acceptable salt thereof: wherein, R1 is trifluoromethyl, trifluoromethoxy, or pentafluorosulfanyl; each R2 is independently a hydrogen atom or methyl which is optionally substituted by one hydroxyl or one saturated heterocyclyl having four to six ring-forming atoms; R3 is a hydrogen atom, halogen atom, C1-C3 alkyl, saturated heterocyclyl having four to six ring-forming atoms and optionally having an oxo group, or R5O—; and R4 is phenyl, pyridyl, pyridazinyl, or pyrimidinyl, which phenyl, pyridyl, pyridazinyl, or pyrimidinyl is optionally substituted by one R6.

Abstract: A compound has inhibitory activity on Discoidin Domain Receptor 1. The compound includes a urea derivative represented by the formula below or a pharmaceutically acceptable salt thereof.

Abstract: A compound has retinoid-related orphan receptor ? antagonist activity and shows a therapeutic effect or a preventive effect on autoimmune diseases such as multiple sclerosis or psoriasis or allergic diseases, including allergic dermatitis or the like, such as contact dermatitis or atopic dermatitis. The cyclic amine derivative is represented by the formula or a pharmacologically acceptable salt thereof.

Abstract: A method of treating or preventing multiple sclerosis includes administering a therapeutically effective amount of a cyclohexane derivative represented by Formula (I): wherein A is a substituent represented by Formula (IIa) or (IIb): R1 and R2 are each independently a hydrogen atom, chlorine atom, C1-C3 haloalkyl, C1-C4 alkyl, C1-C4 alkoxy, or cyano; R3 is a hydrogen atom or chlorine atom; R4 is a fluorine atom, hydroxymethyl, or hydroxyl; R5 and R6 are each independently a hydrogen atom, fluorine atom, C1-C3 haloalkyl, carboxyl, methoxycarbonyl, ethoxycarbonyl, C1-C4 alkoxy, hydroxyl, or C2-C5 alkylcarbonyloxy, or optionally together form oxo; R7 and R8 are each independently a hydrogen atom or fluorine atom; Y is an oxygen atom or sulfur atom; and Z is a nitrogen atom or methine or a pharmaceutically acceptable salt thereof to a mammal.

Abstract: A compound has inhibitory activity on Discoidin Domain Receptor 1. A urea derivative is represented by the formula (I) or a pharmaceutically acceptable salt thereof: wherein, R1 is trifluoromethyl, trifluoromethoxy, or pentafluorosulfanyl; each R2 is independently a hydrogen atom or methyl which is optionally substituted by one hydroxyl or one saturated heterocyclyl having four to six ring-forming atoms; R3 is a hydrogen atom, halogen atom, C1-C3 alkyl, saturated heterocyclyl having four to six ring-forming atoms and optionally having an oxo group, or R5O—; and R4 is phenyl, pyridyl, pyridazinyl, or pyrimidinyl, which phenyl, pyridyl, pyridazinyl, or pyrimidinyl is optionally substituted by one R6.

Abstract: A method of treating or preventing multiple sclerosis includes administering a therapeutically effective amount of a cyclohexane derivative represented by Formula (I): wherein A is a substituent represented by Formula (IIa) or (IIb): R1 and R2 are each independently a hydrogen atom, chlorine atom, C1-C3 haloalkyl, C1-C4 alkyl, C1-C4 alkoxy, or cyano; R3 is a hydrogen atom or chlorine atom; R4 is a fluorine atom, hydroxymethyl, or hydroxyl; R5 and R6 are each independently a hydrogen atom, fluorine atom, C1-C3 haloalkyl, carboxyl, methoxycarbonyl, ethoxycarbonyl, C1-C4 alkoxy, hydroxyl, or C2-C5 alkylcarbonyloxy, or optionally together form oxo; R7 and R8 are each independently a hydrogen atom or fluorine atom; Y is an oxygen atom or sulfur atom; and Z is a nitrogen atom or methine or a pharmaceutically acceptable salt thereof to a mammal.

Abstract: A therapeutic or prophylactic agent for multiple sclerosis includes as an effective component a cyclohexane derivative represented by Formula (I): wherein A is a substituent represented by Formula (IIa) or (IIb): R1 and R2 are each independently a hydrogen atom, chlorine atom, C1-C3 haloalkyl, C1-C4 alkyl, C1-C4 alkoxy, or cyano; R3 is a hydrogen atom or chlorine atom; R4 is a fluorine atom, hydroxymethyl, or hydroxyl; R5 and R6 are each independently a hydrogen atom, fluorine atom, C1-C3 haloalkyl, carboxyl, methoxycarbonyl, ethoxycarbonyl, C1-C4 alkoxy, hydroxyl, or C2-C5 alkylcarbonyloxy, or optionally together form oxo; R7 and R8 are each independently a hydrogen atom or fluorine atom; Y is an oxygen atom or sulfur atom; and Z is a nitrogen atom or methane or a pharmaceutically acceptable salt thereof.

Abstract: A therapeutic or prophylactic agent for allergic dermatitis is disclosed. The therapeutic or prophylactic agent comprises as an effective ingredient a glycine derivative having a specific structure or a pharmaceutically acceptable salt thereof, for example, the below-described compound [(E)-2-(2,6-dichlorobenzamido)-5-[4-(isopropyl-pyrimidin-2-ylamino)phenyl]pent-4-enoic acid]. The therapeutic or prophylactic agent for allergic dermatitis according to the present invention has high therapeutic or prophylactic effect.

Abstract: A 2,3-dihydro-1H-indene-2-yl urea represented by Formula (Ia) or a pharmaceutically acceptable salt thereof:

Abstract: A therapeutic or prophylactic agent for allergic dermatitis is disclosed. The therapeutic or prophylactic agent comprises as an effective ingredient a glycine derivative having a specific structure or a pharmaceutically acceptable salt thereof, for example, the below-described compound [(E)-2-(2,6-dichlorobenzamido)-5-[4-(isopropyl-pyrimidin-2-ylamino)phenyl]pent-4-enoic acid]. The therapeutic or prophylactic agent for allergic dermatitis according to the present invention has high therapeutic or prophylactic effect.

Abstract: A 2,3-dihydro-1H-indene-2-yl urea derivative represented by Formula (Ia) or a pharmaceutically acceptable salt thereof:

Abstract: A therapeutic or prophylactic agent for leukemia is disclosed. The therapeutic or prophylactic agent comprises as an effective ingredient a glycine derivative having a specific structure or a pharmaceutically acceptable salt thereof, for example, the below-described compound [(E)-2-(2,6-dichlorobenzamido)-5-[4-(isopropyl-pyrimidin-2-ylamino)phenyl]pent-4-enoic acid]. The therapeutic or prophylactic agent for leukemia according to the present invention shows the excellent absorbability and in vivo stability when orally administered, and exhibits prominent therapeutic or prophylactic effects.

Abstract: A therapeutic or prophylactic agent for multiple sclerosis is disclosed. The therapeutic or prophylactic agent comprises as an effective ingredient a glycine derivative having a specific structure or a pharmaceutically acceptable salt thereof, for example, the below-described compound [(E)-2-(2,6-dichlorobenzamido)-5-[4-(isopropyl-pyrimidin-2-ylamino)phenyl]pent-4-enoic acid]. The therapeutic or prophylactic agent for multiple sclerosis according to the present invention shows the excellent absorbability and in vivo stability when orally administered, and exhibits high therapeutic or prophylactic effects.

Abstract: This invention relates to a pharmaceutical comprising as an effective ingredient an arylmethylene urea exemplified by the following formula: or a pharmaceutically acceptable salt thereof. The arylmethylene urea and the pharmaceutically acceptable salts thereof are useful for therapy or prophylaxis of inflammatory bowel disease and overactive bladder.

Abstract: A therapeutic or prophylactic agent for multiple sclerosis is disclosed. The therapeutic or prophylactic agent comprises as an effective ingredient a glycine derivative having a specific structure or a pharmaceutically acceptable salt thereof, for example, the below-described compound [(E)-2-(2,6-dichlorobenzamido)-5-[4-(isopropyl-pyrimidin-2-ylamino)phenyl]pent-4-enoic acid]. The therapeutic or prophylactic agent for multiple sclerosis according to the present invention shows the excellent absorbability and in vivo stability when orally administered, and exhibits high therapeutic or prophylactic effects.